Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions: Mitapivat, Mitapivat-matching placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Subacromial Impingement Syndrome
Interventions: Standard Physical Therapy Treatment, Dry Needling, Sham Dry Needling; Procedure
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Depression, Anxiety
Interventions: Supporting Our Valued Adolescents (SOVA), Enhanced Usual Care; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 19 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rosacea
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Clearwater, Florida • Miami, Florida • Miramar, Florida + 4 more

Conditions: Treatment Resistant Depression
Interventions: Allo-hMSCs, Placebo; Drug
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: Gusacitinib; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Severe Preeclampsia, Eclampsia Preeclampsia
Interventions: Levetiracetam, magnesium sulfate; Drug
Lead sponsor: Nebraska Methodist Health System; Other
Eligibility: 19 Years and older · Female only
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: ONO-2952, Placebo comparator; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Conditions: Healthy Volunteers
Interventions: BMS-986278, Placebo, Moxifloxacin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Cardiac Surgery Subjects
Interventions: EIT Guided PEEP Trial; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Cancer, Fertility Preservation
Interventions: Multi-component oncofertility care intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 0 Years to 50 Years
Enrollment: 2,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Duarte, California • El Centro, California • La Jolla, California + 1 more

Conditions: Migraine
Interventions: Stimulation of the Occipital Nerves; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 8 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 4
States / cities: Newington, New Hampshire • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2409021, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: Buena Park, California • Huntington Park, California • Westlake Village, California + 10 more

Conditions: Urinary Retention Postoperative
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years and older · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: LY3848575, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Orthopedic Devices Associated With Misadventures
Interventions: Tenex Procedure, Open Debridement Surgical Intervention Treatment Plan; Procedure
Lead sponsor: Sean Mc Millan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Burlington, New Jersey • Cherry Hill, New Jersey • Moorestown, New Jersey + 4 more

Conditions: Opiate Addiction
Interventions: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Newport Beach, California • San Diego, California • San Francisco, California + 20 more

Conditions: Microscopic Hematuria
Interventions: Premarin vaginal estrogen cream, Placebo vaginal cream; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Subjects
Interventions: GSK706769; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Arthroplasties, Knee Replacement
Interventions: Inelastic adjustable compression garment (INCOM), Elastic compression garment (CONTROL); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 120 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: HCV Infection
Interventions: ABT-450, ritonavir, Placebo for ABT-450, Placebo for ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Maitland, Florida

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

Dry Needling for Sub Acromial Pain Syndrome

Supporting Our Valued Adolescents Pilot Randomized Controlled Trial

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

Effect of PEEP on Cardiac Function

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

Occipital Nerve Stimulation in the Treatment of Migraine

A Study for Participants With Type 2 Diabetes Mellitus

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

A Study of LY3848575 in Healthy Participants

Randomized Controlled Trial (RCT) of Open Debridement Versus Tenex

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

GSK706769 A First Time in Human Study For Males and Females

Swelling Management After Knee Replacement

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD